<DOC>
	<DOCNO>NCT03046056</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy filgotinib , compare placebo , establish clinical remission participant Crohn 's disease involve small bowel . Participants option enter separate long-term extension study meet eligibility requirement .</brief_summary>
	<brief_title>Efficacy Safety Filgotinib Treatment Small Bowel Crohn 's Disease ( SBCD )</brief_title>
	<detailed_description />
	<mesh_term>Crohn Disease</mesh_term>
	<criteria>Key Males nonpregnant , nonlactating female , age 18 75 year , inclusive base date screen visit Moderately severely active CD Minimum duration CD least 6 month Presence diseased SB segment least 1 follow segment : terminal ileum , distal ileum , jejunum Patients additional colonic involvement CD permit study long SBCD present Previously demonstrate inadequate clinical response , loss response , intolerance least 1 follow agent ( depend current country treatment recommendations/guidelines ) : Corticosteroids Immunomodulators Tumor necrosis factoralpha ( TNFÎ± ) antagonists Vedolizumab Willing able undergo magnetic resonance enterography ( MRE ) per protocol requirement Key Presence symptomatic clinically significant ( eg , obstructive symptomatic ) strictures stenosis . Presence fistulae Evidence short bowel syndrome Presence ulcerative colitis , indeterminate colitis , ischemic colitis , fulminant colitis , toxic megacolon History total colectomy , hemicolectomy , presence ileostomy colostomy , likely requirement surgery study Use prohibit concomitant medication describe study protocol Active tuberculosis ( TB ) history latent TB treat Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>